ArticleFrontiers in immunology2018
Third-Party Allogeneic Mesenchymal Stromal Cells Prevent Rejection in a Pre-sensitized High-Risk Model of Corneal Transplantation.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Pooled it
- Integrated Conservation Strategies for the Oravka Chicken: Advances in Cryopreservation Technologies for Endangered Poultry Genetic Resources-A Literature Review.Animals : an open access journal from MDPI · 2026Review
- Review
- Mesenchymal Stem Cell Secretome Effectiveness in Healing Chronic Tendon Injury: Procollagen Analysis and Histopathology in Rat Tendons.Stem cells and cloning : advances and applications · 2025Article
- Cell-based therapy in the treatment of musculoskeletal diseases.Stem cells translational medicine · 2024Review
- Peripheral blood immune cell profiling of acute corneal transplant rejection.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022Article
- Mesenchymal stem cells augment regulatory T cell function via CD80-mediated interactions and promote allograft survival.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022Article
- Mesenchymal stromal cells for the treatment of ocular autoimmune diseases.Progress in retinal and eye research · 2021Review
- Role of Immune Cell Diversity and Heterogeneity in Corneal Graft Survival: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2021Review
- Effects of living and metabolically inactive mesenchymal stromal cells and their derivatives on monocytes and macrophages.World journal of stem cells · 2021Review
- Subconjunctival administration of low-dose murine allogeneic mesenchymal stromal cells promotes corneal allograft survival in mice.Stem cell research & therapy · 2021Article
- Mesenchymal stromal cells for corneal transplantation: Literature review and suggestions for successful clinical trials.The ocular surface · 2021Review
- CD73 expression is critical to therapeutic effects of human endometrial regenerative cells in inhibition of cardiac allograft rejection in mice.Stem cells translational medicine · 2021Article
- Human fetal liver MSCs are more effective than adult bone marrow MSCs for their immunosuppressive, immunomodulatory, and Foxp3Stem cell research & therapy · 2021Article
- Cellular therapies in organ transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2021Review
- From Mesenchymal Stromal/Stem Cells to Insulin-Producing Cells: Immunological Considerations.Frontiers in immunology · 2021Review
- Comparing the Therapeutic Potential of Stem Cells and their Secretory Products in Regenerative Medicine.Stem cells international · 2021Review
- Current Desensitization Strategies in Heart Transplantation.Frontiers in immunology · 2021Review
- Cellular Therapies in Solid Organ Allotransplantation: Promise and Pitfalls.Frontiers in immunology · 2021Review
- Potential of mesenchymal stem cells as topical immunomodulatory cell therapies for ocular surface inflammatory disorders.Stem cells translational medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-risk cornea transplant recipients represent a patient population with significant un-met medical need for more effective therapies to prevent immunological graft rejection due to heightened anti-donor immune response. In this study, a rat model of pre-existing anti-donor immunity was developed in which corneal allografts were rejected earlier than in non-pre-sensitized recipients. In this model, third-party (non-donor, non-recipient strain) allogeneic mesenchymal stromal cells (allo-MSC) were administered intravenously 7 and 1 days prior to transplantation. Rejection-free graft survival to 30 days post-transplant improved from 0 to 63.6% in MSC-treated compared to vehicle-treated control animals (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.